| Similar Articles |
|---|
 |
The Motley Fool
July 26, 2006
Ryan Fuhrmann |
Sigma-Aldrich's Steady Growth Growth at this life science company is steady, not spectacular. With a current stock price of $67.78, the shares trade at about 17 times projected earnings.   |
The Motley Fool
October 30, 2006
Ralph Casale |
Sigma-Aldrich Ekes Out Organic Growth Share buybacks and a dividend help offset some mixed news from this biotech/chemical company. Investors, take note. |
The Motley Fool
April 20, 2011
Cindy Johnson |
Don't Miss Out on This Underappreciated Tech Winner IBM is planning the growth ... and outgrowing the plan. |
The Motley Fool
May 2, 2006
Stephen D. Simpson |
Still Fishing for Value at Fisher At the right price, this would be an interesting play on health care and biomedical research. Investors, take note. |
The Motley Fool
June 3, 2005
Selena Maranjian |
Your Friend, the P/E Ratio The P/E is informative, but don't rely on it too much. There are many other numbers to examine when studying a stock. |
The Motley Fool
February 15, 2006
Stephen D. Simpson |
A Play on the Building Blocks of R&D Sigma-Aldrich might be suitable for those looking to play biological R&D without picking a specific pharma or biotech stock. |
The Motley Fool
February 15, 2005 |
P/E Ratio Dynamics There's some logic for investors behind seemingly wacky P/E ratios. |
The Motley Fool
January 12, 2004
Selena Maranjian |
Your Friend, the P/E Ratio Let it help you evaluate stock prices. |
The Motley Fool
September 2, 2010
Seth Jayson |
Is Sigma-Aldrich Growing or Slowing? Look here for a clue as to the chemical company's health. |
The Motley Fool
August 10, 2004 |
"Diluted" vs. "Basic" Earnings The terms reflect some interesting changes in how companies report their earnings. Learn the difference so you can focus on the right numbers when investing. |
The Motley Fool
February 7, 2008
Brian Orelli |
Invitrogen Integrates After a rough 2006 in which it struggled to integrate its acquisitions, Invitrogen used 2007 to show why it made all of its purchases. |
The Motley Fool
January 6, 2005
Dave Marino-Nachison |
Oxford Blues The apparel maker is pulling back its fiscal 2005 EPS estimates. Oxford still looks like a company that's growing in the right places and making smart strategic moves. Investors seem to agree. |
The Motley Fool
February 14, 2006
Stephen D. Simpson |
Looking for a Hook at Fisher Scientific Growth and market share are great, but return on invested capital tells the tale in the end. Investors, think twice before putting your money with this one. |
The Motley Fool
October 15, 2004 |
Don't Be Fooled by Earnings Growth Companies have ways to boost earnings without boosting sales. |
The Motley Fool
December 2, 2004
Sam Subramanian |
Stodgy Stocks Can Grow Your Portfolio By explicitly considering the odds of a company growing faster than expected, investors can reduce the agony of watching share price and earnings-per-share trends diverge. Here are some mainstream ideas to get started in the right direction. |
The Motley Fool
January 10, 2012
Alexander Crawford |
Deutsche Analyst Expects Q4 Earnings to Surprise: 10 Companies to Watch Do you think these stocks will surprise the market once more? |
The Motley Fool
September 20, 2006 |
All EPS Increases Aren't Alike Don't assume that a stock's surging EPS is great news. |
Chemistry World
September 26, 2014
Rebecca Trager |
Merck KGaA to buy Sigma--Aldrich German chemicals conglomerate Merck KGaA has agreed to buy US specialty chemicals company Sigma -- Aldrich for $17 billion |
